Skip to content
OpenCapital
Get started

Nektar Therapeutics NKTR Payment Of Transaction Costs And Working Capital Adjustment From The Sale Of Manufacturing Facility

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.19B+1,531%

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%—
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept nktr:PaymentOfTransactionCostsAndWorkingCapitalAdjustmentFromTheSaleOfManufacturingFacility.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Nektar Therapeutics's payment of transaction costs and working capital adjustment from the sale of manufacturing facility?
Nektar Therapeutics (NKTR) reported payment of transaction costs and working capital adjustment from the sale of manufacturing facility of $0 in Q1 2026.
How has Nektar Therapeutics's payment of transaction costs and working capital adjustment from the sale of manufacturing facility changed year-over-year?
Nektar Therapeutics's payment of transaction costs and working capital adjustment from the sale of manufacturing facility decreased by 100.0% year-over-year, from $697K to $0.